The nurse is teaching a client with type 1 diabetes mellitus about the onset, peak, and duration of a new prescription for glargine insulin. If the insulin is self administered at 0800, when is the client most likely to experience hypoglycemia?

A. Midmorning: Short-acting and some intermediate-acting insulins peak during midmorning, but glargine insulin is long-acting and designed to provide a steady level of insulin without a pronounced peak, making midmorning hypoglycemia unlikely. B. Shortly after midnight: Although nighttime hypoglycemia can occur with other types of insulin, glargine releases slowly over 24 hours, maintaining a relatively flat serum insulin concentration and reducing the risk of nocturnal hypoglycemia. C. No peak occurs: Glargine insulin is formulated to have no pronounced peak, instead providing a continuous, steady release over approximately 24 hours. This flat profile minimizes the risk of sudden hypoglycemic episodes associated with peak insulin levels. D. Midafternoon: Hypoglycemia during midafternoon is more characteristic of short-acting or intermediate-acting insulins, not glargine. Since glargine has a steady release, it does not typically cause time-specific hypoglycemia like shorter-acting insulins do.